Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2021 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference

HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
February 17, 2021 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

Seclidemstat safety profile affirmed; Recommended Phase 2 dose established Demonstrated preliminary evidence of seclidemstat drug activity in subset of Ewing-related sarcoma patients HOUSTON, Feb. ...
February 16, 2021 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Present at BIO CEO & Investor Digital Conference

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid...
January 21, 2021 08:05 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
January 15, 2021 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference

HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
January 13, 2021 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas

HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
December 22, 2020 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Participate in Biotech Showcase Digital and BIO @ JPM During "J.P. Morgan Week 2021"

HOUSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid...
December 11, 2020 11:32 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat

HOUSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
December 10, 2020 09:28 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Receives First Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
November 17, 2020 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Participate in A.G.P.’s Virtual Healthcare Symposium

HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...